Empagliflozin for Dialysis Patients with Kidney Failure
Trial Summary
The protocol does not specify if you need to stop taking your current medications. However, it does not mention any specific requirements to stop or continue existing medications.
The available research shows that empagliflozin, while primarily studied for heart failure and diabetes, has shown benefits in patients with chronic kidney disease (CKD). Specifically, the EMPA-KIDNEY trial found that empagliflozin reduced the progression of kidney disease or the risk of cardiovascular death over two years. This suggests that empagliflozin could be effective for patients with kidney failure, even though the direct evidence for dialysis patients is not detailed in the provided information.
12345Empagliflozin, also known as Jardiance, has been studied for safety in patients with type 2 diabetes and chronic kidney disease (CKD) in placebo-controlled clinical trials. It is approved for reducing cardiovascular death and hospitalization in heart failure patients, even without diabetes. While generally well-tolerated, it has side effects and contraindications, particularly fluid deficits, which should be monitored. The EMPA-KIDNEY trial is investigating its effects on renal and cardiovascular disease in CKD patients.
12367Yes, Empagliflozin is a promising drug for dialysis patients with kidney failure. It helps protect the heart and kidneys, reduces the risk of heart failure, and slows down kidney disease progression. It is also effective in managing diabetes and can lower blood pressure and body weight.
12348Eligibility Criteria
This trial is for adults with severe chronic kidney disease (ESKD) who have been on dialysis for at least 3 months, regardless of whether they have diabetes. It's not open to those with active cancer treatment, unhealed skin ulcers on the lower body, allergies to empagliflozin, pregnancy, type 1 diabetes, current IV antibiotic therapy for infections, a history of Fournier's gangrene or recent severe hypoglycemia.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
- Cardiovascular risk reduction
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction
- Chronic kidney disease
- Type 2 diabetes mellitus
- Heart failure with reduced ejection fraction